The great Ozempic divide has arrived. Canadians are gliding through healthcare aisles with generic semaglutide for a fraction of the American price, while US citizens fork over premiums that would make a Victorian banker blush. The UK’s NHS pricing model, long the envy of single-payer fantasists, is now under the microscope. And the diagnosis is not pretty: the United States has become the cash cow for global pharmaceutical giants, and the Canadian bargain is simply a reminder of a system that prioritises public health over shareholder dividends.
Let us dispense with the sentimental rubbish. The American healthcare system is not a system at all. It is a feudal patchwork of insurers, hospital conglomerates, and patent-protected monopolies. The fact that Novo Nordisk can sell the same drug in Canada for CAD $200 a month while US patients pay USD $900 is not a mystery. It is a scandal. The Canadians, with their cautious, polite socialism, have negotiated bulk prices and leveraged national health systems. The Americans, too proud or too fractured to do the same, are left holding the bag.
Now the NHS is watching. British boffins, ever eager to export their cost-control wizardry, are scrutinising how Canada managed to undercut even the UK’s already cheap list prices. The implication is clear: the NHS might be able to squeeze more value from its own negotiations. But the real lesson is for the Americans. You cannot have a system built on the myth of free markets and then complain when the market exploits you. The pharmaceutical industry is not a charity. It is a business. And businesses charge what the traffic will bear.
Consider the historical parallel. In the late Roman Empire, the annona, the grain dole, was a mechanism to buy social peace. The elite grumbled at the cost, but they understood that cheap bread was the price of order. Today, the US has no annona for insulin or GLP-1s. Instead, it has a patchwork of discount cards and shameful GoFundMe campaigns. Rome fell when it forgot that some things are too essential to be left to the market. The US is repeating the mistake with Ozempic.
Intellectual decadence plays a part. The American right clings to the idea that price controls are socialist tyranny. The left is too busy fighting for theoretical purity to notice the actual suffering. Meanwhile, the middle class bears the cost. The Canadian model is not perfect, but it is functional. The UK model is not flawless, but it works. The US model is a catastrophe dressed in the robes of liberty.
So what is to be done? The obvious answer is a national negotiation floor for essential medicines. But that would require a Congress that remembers the concept of the common good. Short of that, the American patient is left to envy the Canadian neighbour and curse the system. The NHS should take notes, but it should also look to its own future. Generic competition is coming, but the patent fortress remains. The only lasting solution is a dismantling of the intellectual property regime that allows this profiteering. But that would be revolutionary. And we know how revolutions end.
For now, the Ozempic gap is a mirror. It reflects a nation that cannot decide if healthcare is a right or a luxury. Canada has decided. The UK has decided. America remains stuck in a debate that belongs in the 19th century. The Victorians, for all their faults, had a sense of civic obligation. We have become a nation of customers, not citizens. And that is a prescription for decline.
